

Special Issue

Antibiotics against Tuberculosis

Message from the Guest Editor

Tuberculosis remains the major cause of death worldwide by an infectious agent. According to the World Health Organization, 1.5 million people died from tuberculosis in 2018. Furthermore, the increase in multidrug-resistant (MDR-TB) and extremely drug-resistant (XDR-TB) cases is alarming and continues to constitute a public health crisis. Despite the advances that have taken place in the last years, with the inclusion of much needed new antibiotics, considerable progress must still be made in order to tackle this deadly disease. We urgently need new antibiotics with better efficacy, fewer side effects, and preferably the ability to shorten treatment. In this issue, we will cover the latest advances in the research of drugs to fight *Mycobacterium tuberculosis*. Thus, this Special Issue will be covering but not limited to: **Drug discovery, drug screening, synthesis/isolation/repurposing of antimicrobials, antimicrobial resistance, mechanism of action, and new drug regimens/combinations**. We especially encourage the submission of original articles and reviews.

Guest Editor

Dr. Juan Manuel Belardinelli

Department of Microbiology, Immunology & Pathology, Colorado State University, Fort Collins, CO 0523-1682, USA

Deadline for manuscript submissions

closed (30 April 2020)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/27973

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)